USPTO rejects MonoSol's patent infringement claims against BDSI

NewsGuard 100/100 Score

The United States Patent & Trademark Office (USPTO) has informed BioDelivery Sciences International, Inc. (Nasdaq: BDSI) that it has rejected all claims by MonoSol Rx, LLC (MonoSol) in its US Patent No. 7,425,292 (the '292 Patent) which is currently being asserted against BDSI and its commercial partners for ONSOLIS.  The action by the USPTO represents an additional positive development for BDSI in its case with MonoSol.

MonoSol filed a patent infringement lawsuit against BDSI in November 2010 based on MonoSol's '588 Patent.  Following BDSI's request for a reexamination of this patent, the USPTO in November of last year rejected all 191 claims.  In September 2011, MonoSol added two additional patents (the '292 Patent and the '891 Patent) to its case against BDSI.  In its action, MonoSol claimed that BDSI's confidential, proprietary manufacturing process for ONSOLIS infringes on the thin film manufacturing process claimed in its '588 Patent, and subsequently, its '292 and '891 Patents. 

The current action presently taken by the USPTO rejects all 22 claims of MonoSol's '292 Patent.  In doing so, the USPTO has now rejected all claims in two ('588 and '292) of the three patents asserted against BDSI.  Reexamination of the third MonoSol patent ('891), which is part of the same family of patents, has also been requested and an outcome is expected shortly. 

SOURCE BioDelivery Sciences International, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
UQ's AMTAR hub advances the development of hyper-accurate cancer drugs